![]() | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||
|
Thrombolysis isn't just pharma, it can also be done though devices --e.g. Those that use HIFU. -- 216.9.250.104 ( talk) 23:21, 29 November 2007 (UTC)
I suggest merging Thrombolytic drug into Thrombolysis. There's an awful lot of overlap between the two articles at present. Both are quite short and both have been around since 2004. Comments? Qwfp ( talk) 16:08, 22 April 2009 (UTC)
Both could be merged into a subheading under Fibrinolysis, a full entry that provides an extensive set of references. 68.173.53.167 ( talk) 20:56, 13 January 2010 (UTC)
Both of these articles really belong under Fibrinolysis as the drugs interact with this system. —Preceding unsigned comment added by 99.149.199.86 ( talk) 01:22, 26 January 2011 (UTC)
doi: 10.1111/j.1365-2141.2009.07914.x review on dosing and indications for thrombolysis in children. JFW | T@lk 21:05, 22 December 2009 (UTC)
the following is unsourced; there is also no "principles" section in MEDMOS, and I am not sure what the goal of this content is
Formation of blood clots lies at the basis of a number of serious diseases (see below). By breaking down the clot, the disease process can be arrested, or the complications reduced. While other anticoagulants (such as heparin) prevent the "growth" of a clot, thrombolytic agents actively reduce the size of the clot.
Most thrombolytic agents work by activating the enzyme plasminogen, which clears the cross-linked fibrin mesh (the backbone of a clot). This makes the clot soluble and subject to further proteolysis by other enzymes, and restores blood flow over occluded blood vessels.
Principles of preventing blood clots from forming are handled by clinicians who assess the risk and if the risk of developing blood clots, the use of thrombolytic agents may be prevented. Oftentimes, thombolytic interventions are used with thrombosis prophylaxis.
-- Jytdog ( talk) 01:04, 24 December 2016 (UTC)
I think thrombolytic drug and contraindications to thrombolysis should both be merged here. JFW | T@lk 00:28, 29 December 2016 (UTC)
Already largely duplicated on target page where it would be better presented Iztwoz ( talk) 08:24, 29 December 2016 (UTC)
Merge reasonable here. Doc James ( talk · contribs · email) 06:38, 31 December 2016 (UTC)
Done. Doc James ( talk · contribs · email) 07:32, 18 February 2017 (UTC)
https://www.biologydiscussion.com/dna/pharmaceutical-products-of-recombinant-dna-technology/10015 5.65.66.124 ( talk) 12:54, 5 July 2021 (UTC)
![]() | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||
|
Thrombolysis isn't just pharma, it can also be done though devices --e.g. Those that use HIFU. -- 216.9.250.104 ( talk) 23:21, 29 November 2007 (UTC)
I suggest merging Thrombolytic drug into Thrombolysis. There's an awful lot of overlap between the two articles at present. Both are quite short and both have been around since 2004. Comments? Qwfp ( talk) 16:08, 22 April 2009 (UTC)
Both could be merged into a subheading under Fibrinolysis, a full entry that provides an extensive set of references. 68.173.53.167 ( talk) 20:56, 13 January 2010 (UTC)
Both of these articles really belong under Fibrinolysis as the drugs interact with this system. —Preceding unsigned comment added by 99.149.199.86 ( talk) 01:22, 26 January 2011 (UTC)
doi: 10.1111/j.1365-2141.2009.07914.x review on dosing and indications for thrombolysis in children. JFW | T@lk 21:05, 22 December 2009 (UTC)
the following is unsourced; there is also no "principles" section in MEDMOS, and I am not sure what the goal of this content is
Formation of blood clots lies at the basis of a number of serious diseases (see below). By breaking down the clot, the disease process can be arrested, or the complications reduced. While other anticoagulants (such as heparin) prevent the "growth" of a clot, thrombolytic agents actively reduce the size of the clot.
Most thrombolytic agents work by activating the enzyme plasminogen, which clears the cross-linked fibrin mesh (the backbone of a clot). This makes the clot soluble and subject to further proteolysis by other enzymes, and restores blood flow over occluded blood vessels.
Principles of preventing blood clots from forming are handled by clinicians who assess the risk and if the risk of developing blood clots, the use of thrombolytic agents may be prevented. Oftentimes, thombolytic interventions are used with thrombosis prophylaxis.
-- Jytdog ( talk) 01:04, 24 December 2016 (UTC)
I think thrombolytic drug and contraindications to thrombolysis should both be merged here. JFW | T@lk 00:28, 29 December 2016 (UTC)
Already largely duplicated on target page where it would be better presented Iztwoz ( talk) 08:24, 29 December 2016 (UTC)
Merge reasonable here. Doc James ( talk · contribs · email) 06:38, 31 December 2016 (UTC)
Done. Doc James ( talk · contribs · email) 07:32, 18 February 2017 (UTC)
https://www.biologydiscussion.com/dna/pharmaceutical-products-of-recombinant-dna-technology/10015 5.65.66.124 ( talk) 12:54, 5 July 2021 (UTC)